PATENT CLAIM ANALYSIS

Application Number: 15909521
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["544", "331000"]

Abstract:
The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.

Claim (Index 26):
The compound of  claim 25 , wherein TKI is capable of binding to c-ABL and/or BCR-ABL.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 90.0
- Lexical Diversity: 1.58824
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15341275', '14822309', '13211026', '15881318', '15400766']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.764880763180203
- 35 USC 102 Novelty (BERT): 0.6714085978157663
- Combined Prediction Score: 0.7555335466437594
- Mean Citation Score: 345.960142
- Max Citation Score: 831.4325
- Similarity Product: 625.5523035156726

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test